Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiac Safety and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KCNH2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KCNH2 Extracellular Loop Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View KCNH2 Products |
| Gene Delivery | KCNH2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and electrophysiology assays. |
View KCNH2 Products |
| Benchmark Ab | Anti-KCNH2 Recombinant Antibody Recombinant positive control for flow cytometry and functional blocking. |
View KCNH2 Products |
| Validator | KCNH2 siRNA Set For knockdown verification in target specificity assays. |
View KCNH2 Products |
| Related Target A | SCN5A Critical cardiac sodium channel; essential for comprehensive in vitro proarrhythmia assay (CiPA) panels. |
View SCN5A Products |
| Related Target B | CACNA1C L-type calcium channel; paired with KCNH2 for cardiac safety and QT prolongation risk assessment. |
View CACNA1C Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent screening of multi-pass transmembrane protein | Lentivirus-driven full-length expression ensures native membrane integration and correct tertiary folding. |
| Off-target cardiotoxicity profiling | High-titer, sequence-verified lentiviral vectors enable consistent, stable cell line generation for high-throughput patch clamp or thallium flux assays. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control reagents included |
| False Positives | Validated siRNA sets included for target-specific knockdown verification |
Live KCNH2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The landscape for KCNH2 (hERG) therapeutics is divided into two distinct domains: its foundational role as the gold-standard cardiac safety counter-screen, and its emerging potential as a therapeutic oncology target. In safety screening, the regulatory push toward the Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative has heightened the demand for highly stable, human-derived cell lines to replace low-throughput manual patch-clamp protocols. Concurrently, KCNH2 is recognized as overexpressed in several solid tumors and leukemia, driving interest in targeted monoclonal antibodies and antibody-drug conjugates (ADCs) designed to selectively target tumor-specific hERG conformations while avoiding cardiac ion channel disruption.
"The race for KCNH2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to conformation-selective antibodies and safety-screening cell platforms. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific extracellular epitopes to bypass systemic cardiotoxicity."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Safety) | Global Pharma (AstraZeneca, Pfizer) | Cardiotoxicity Counter-screening | Functional Electrophysiology (Need Lentivirus for Stable Cell Line) |
| Monoclonal Antibody | Academic Institutes, Biotech Startups | Colorectal Cancer, Glioblastoma | Conformation-Specific Binding (Need Sequence Verified Extracellular Loop Proteins) |
| siRNA / Gene Therapy | RNAi Therapeutics Developers | Cardiac Channelopathies, Long QT Syndrome | Knockdown Validation (Need Sequence-Verified siRNA Sets) |